These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 11950440)
1. Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors. Iakovou I; Dangas G; Mehran R; Lansky AJ; Kobayashi Y; Adamian M; Polena S; Collins MB; Roubin GS; Stone GW; Leon MB; Moses JW Am J Cardiol; 2002 Apr; 89(8):976-9. PubMed ID: 11950440 [No Abstract] [Full Text] [Related]
2. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950 [TBL] [Abstract][Full Text] [Related]
3. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). Assali AR; Salloum J; Sdringola S; Moustapha A; Ghani M; Hale S; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR Am J Cardiol; 2001 Oct; 88(8):884-6, A6. PubMed ID: 11676953 [No Abstract] [Full Text] [Related]
4. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment. Tcheng JE Am J Cardiol; 1999 May; 83(9A):7E-11E. PubMed ID: 10357575 [No Abstract] [Full Text] [Related]
5. Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes. Kereiakes DJ; McDonald M; Broderick T; Roth EM; Whang DD; Martin LH; Howard WL; Schneider J; Shimshak T; Abbottsmith CW Am Heart J; 2000 Feb; 139(2 Pt 2):S53-60. PubMed ID: 10650317 [No Abstract] [Full Text] [Related]
6. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. Lincoff AM; Califf RM; Topol EJ J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948 [TBL] [Abstract][Full Text] [Related]
7. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy. Wu KK; Willerson JT Circulation; 2001 May; 103(21):2528-30. PubMed ID: 11382717 [No Abstract] [Full Text] [Related]
8. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074 [TBL] [Abstract][Full Text] [Related]
9. A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes. Tcheng JE Am Heart J; 1999 Oct; 138(4 Pt 2):261-2. PubMed ID: 10502231 [No Abstract] [Full Text] [Related]
10. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Tcheng JE Am J Cardiol; 1996 Aug; 78(3A):35-40. PubMed ID: 8751845 [TBL] [Abstract][Full Text] [Related]
12. Glycoprotein IIb/IIIa inhibitors. Stevens M Intensive Crit Care Nurs; 2002 Feb; 18(1):64-6. PubMed ID: 12008879 [TBL] [Abstract][Full Text] [Related]
13. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Sabatine MS; Jang IK Am J Med; 2000 Aug; 109(3):224-37. PubMed ID: 10974186 [TBL] [Abstract][Full Text] [Related]
14. [Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists]. Araujo R; Agustà A Med Clin (Barc); 2000 Oct; 115(11):435-7. PubMed ID: 11093849 [No Abstract] [Full Text] [Related]
15. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L; N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425 [TBL] [Abstract][Full Text] [Related]
17. GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us. Chew DP; Moliterno DJ Cleve Clin J Med; 2001 Dec; 68(12):1017-23. PubMed ID: 11765119 [TBL] [Abstract][Full Text] [Related]
18. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. Lincoff AM Am J Cardiol; 1998 Oct; 82(8B):36P-42P. PubMed ID: 9809890 [TBL] [Abstract][Full Text] [Related]
19. Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use. Pang JT; Fort S; Della Siega A; Cohen EA J Card Surg; 2002; 17(5):425-31. PubMed ID: 12630543 [TBL] [Abstract][Full Text] [Related]
20. Effects on thrombin generation of the platelet glycoprotein IIb/IIIa inhibitors abciximab versus tirofiban during coronary intervention. Ambrose JA; Doss R; Geagea JM; Hawkey MC; Duvuri S; Giedd K; Dominguez A; Coppola J; Nguyen TH; Palla V; Barua RS; Saha DC Am J Cardiol; 2001 May; 87(10):1231-3: A8. PubMed ID: 11356410 [No Abstract] [Full Text] [Related] [Next] [New Search]